Novartis: Multiple Sclerosis, Relapsing-Remitting trials

The registry lists 34 Multiple Sclerosis, Relapsing-Remitting studies with Novartis as lead sponsor. 1 are open to participants now and 19 have results posted.

Phase 2 6Phase 3 5Phase 4 15No phase 8(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMSRecruitingNCT06733922Phase 4
• A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS PatientsCompletedNCT03560739Phase 2Results posted
• Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)CompletedNCT02720107Phase 4Results posted
• Fingolimod Effect on Cytokine and Chemokine LevelsCompletedNCT02373098Phase 4Results posted
• A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple SclerosisTerminatedNCT02038049Phase 2Results posted
• Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple SclerosisTerminatedNCT01874340Phase 2Results posted
• MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus CopaxoneTerminatedNCT01633112Phase 3Results posted
• Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.CompletedNCT01623596Phase 4Results posted
• A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720CompletedNCT01578330Phase 4Results posted
• Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)CompletedNCT01534182Phase 4Results posted
• Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to FingolimodTerminatedNCT01499667Phase 3Results posted
• Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying TherapyCompletedNCT01498887Phase 4Results posted
• Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With DepressionTerminatedNCT01436643Phase 4Results posted
• Fingolimod Versus Interferon Beta 1b in Cognitive SymptomsCompletedNCT01333501Phase 4Results posted
• Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy ChangeCompletedNCT01317004Phase 4Results posted
• Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01185821Phase 2Results posted
• POC-MD MRI-based Trial in Relapsing-remitting Multiple SclerCompletedNCT01051817Phase 2Results posted
• Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00879658Phase 2Results posted
• Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00355134Phase 3Results posted
• Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00289978Phase 3Results posted
• A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated PatientsCompletedNCT06897657
• A Canadian Study of Persistence on Ofatumumab Using Patient Support Program DataCompletedNCT06854341
• Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical PracticeCompletedNCT06737419
• Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 TherapiesCompletedNCT06526000
• A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple SclerosisCompletedNCT06395909
• ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS PatientsActive, not recruitingNCT06345157
• A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) ElevationActive, not recruitingNCT05090371Phase 4
• Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg PenCompletedNCT04940065
• Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple SclerosisActive, not recruitingNCT04480853Phase 4
• PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking FingolimodCompletedNCT02335892
• Safety and Efficacy of Fingolimod in MS Patients in ChinaWithdrawnNCT01941004Phase 3
• Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMSWithdrawnNCT01709812Phase 4
• Fingolimod -Response According to Coping - EvaluationCompletedNCT01420055Phase 4
• Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01310166Phase 4